Archives

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting

LONDON— Researchers have shown that endometrial cancer — and hopefully ovarian cancer too — could potentially be detected much earlier than at present — or even prevented altogether — by looking for &

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

AMSTERDAM— New hopes for smokers with lung cancer were raised at the 2013 European Cancer Congress here by research findings from France, Spain and the USA using a new form of immunotherapy to treat r

AMSTERDAM— Organized screening for prostate cancer using the prostate-specific antigen (PSA) test does more harm than good, according to the findings of a French study reported here at the 2013 Europe

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c

LONDON— Intraoperative radiotherapy given at the time of lumpectomy was found to be ‘non-inferior’ to the use of conventional post-operative whole breast external beam radiotherapy and had

AMSTERDAM—Screening men and women for colorectal cancer (CRC) with either fecal occult blood testing (FOBT) or endoscopy markedly lowered disease incidence and mortality in a study of screening patter

AMSTERDAM—Locoregional radiotherapy to the internal mammary and medial supraclavicular lymph nodes in women who had already been treated successfully for their breast cancer with standard regimens — i

AMSTERDAM—Long term survival — three to ten years — in nearly a quarter of patients with unresectable, metastatic or locally advanced melanoma treated with the cytotoxic T-lymphocyte antigen 4 (CTLA-4

IN THIS EDITION: Oral VEGF inhibitor, cediranib, extends life in refractory ovarian cancer Screening has halved colorectal cancer mortality in Europe Diabetes associated with increased risk of inciden

AMSTERDAM—A molecularly-directed approach to treatment decision-making with patients who have metastatic cancers of unknown primary site was being urged at the 2013 European Cancer Congress by researc

AMSTERDAM—The 2013 European Cancer Congress heard that new treatments could extend survival in patients with advanced and metastatic melanoma greatly beyond what has been the norm. Dr. Dirk Schadendor

AMSTERDAM—Postoperative radiotherapy to the internal mammary and supraclavicular lymph nodes in women whose breast cancer has been successfully treated and are at low risk of relapse could save lives

AMSTERDAM—People with diabetes have an increased risk of developing and dying from certain cancers, according to a meta-analysis with two million patients reported at the 2013 European Cancer Congress

AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a myocardial infarction was scrutinised in a debate a

AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in

AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a myocardial infarction was scrutinised in a debate a

CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell hear

CHICAGO— Overall survival improved by more than two-thirds in patients with metastatic melanoma randomised to have GM-CSF added to their ipilimumab therapy. A phase II study in 245 previously treated

PARIS—The fifth in an annual series of multi-sector Worldwide Innovative Networking (WIN) symposia — dedicated to the advancement of personalised medicine — was held here from July 10th to 12th to pro

CHICAGO—A new approach to dealing simultaneously with several of the identified molecular processes taking place in cancer has brought new prospects for extending life in patients with advanced non sm

CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizuma